SAN DIEGO, April 26, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at The American College of Obstetricians and Gynecologists (The College) 59th Annual Clinical Meeting, April 30 May 4.
The College: Walter E. Washington Convention Center, Washington, DC. | |
Monday, May 2: | |
Poster Presentation | |
Abstract: 30 | |
Presenter: Sandra Carson, M.D., Medical Director of Women and Infants’ Center for Reproduction and Infertility and Division Director of Reproductive Endocrinology and Infertility, Women and Infants Hospital, Providence, RI | |
Title: “Increased Weight Loss Seen with Naltrexone SR/ Bupropion SR Combination Across Menopausal Status” | |
Time: 3:00-3:45 p.m. EDT | |
Location: Registration East | |
Tuesday, May 3: | |
Poster Presentation | |
Abstract: 39 | |
Presenter: D. Yvette LaCoursiere, M.D., Assistant Professor, Department of Reproductive Medicine, University of California, San Diego | |
Title: “Naltrexone SR/Bupropion SR Combination Therapy Produces Weight Loss in Overweight/Obese Women” | |
Time: 3:00-3:45 p.m., EDT | |
Location: Registration East | |
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response letter from the FDA for its New Drug Application. The Company is in the process of determining the next steps for Contrave. The Company’s second product, Empatic, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
